AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Prophylactic, Therapeutic, and Diagnostic Remedy for Treatment of Colibacillosis Infection

Technology Benefits: Green Technology! Veterinary: Avian DNA vaccine for colibacillosis (in chickens, turkeys, waterfowl) and potential diagnostics. Human: Potential human vaccine against urinary tract infections caused by E. coli.

Technology Application: Veterinary: Avian DNA vaccine for colibacillosis (in chickens, turkeys, waterfowl) and potential diagnostics. Human: Potential human vaccine against urinary tract infections caused by E. coli.

Detailed Technology Description: None

Supplementary Information: Patent Number: US6087128A
Application Number: US199823221A
Inventor: Nolan, Lisa K. | Horne, Shelley M.
Priority Date: 12 Feb 1998
Priority Number: US6087128A
Application Date: 12 Feb 1998
Publication Date: 11 Jul 2000
IPC Current: A61P003104 | C07K0014245 | C12N001531
US Class: 4350693 | 4350691 | 4353201 | 5360237
Assignee Applicant: NDSU Research Foundation,Fargo
Title: DNA encoding an avian E. coli iss
Usefulness: DNA encoding an avian E. coli iss
Summary: (I) is useful as vaccine for treating and preventing avian septicemic diseases and functions as a marker for diseases causing avian Escherichia coli.
Novelty: Nucleic acid molecule encoding Iss polypeptide isolated from avian Escherichia coli, used to prevent avian septicemic diseases and for diagnostic and control strategies for avian colibacillosis

Industry: Biomedical

Sub Category: DNA/Gene Engineering

*Abstract: Scientists at North Dakota State University have cloned and sequenced the iss (increased serum survival) gene from virulent avian Escherichia coli strains and expressed its encoded ISS polypeptide sequence. This has enabled them to conduct studies in understanding the geneΓÇÖs potential and devise strategies to detect and control the colibacillosis infection that the gene is believed to cause.This invention pertains to the application of this study in formulating DNA vaccines and immunogenic compositions for providing adequate prophylactic, therapeutic and diagnostic remedies against the colibacillosis infection in humans and avian organisms.

*Principal Investigator: Name: Lisa Nolan
Department:

Country/Region: USA

For more information, please click Here